Disease: Mood disorders

Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis

mycolabadmin

This comprehensive analysis of 10 clinical trials shows that psilocybin, a compound from magic mushrooms, can rapidly reduce depression symptoms starting within one day of administration and maintain these benefits for up to 6 months. Higher doses and two treatment sessions produced better results than single lower doses. While psilocybin did raise blood pressure temporarily, it was generally well-tolerated with dropout rates similar to placebo.

Read More »

Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design

mycolabadmin

This review examines how psilocybin-assisted therapy might work for eating disorders by looking at various ways to measure changes in the brain. The authors discuss different brain imaging techniques and other tools that scientists could use to understand how psilocybin affects the brains of people with eating disorders. They emphasize that combining multiple measurement approaches provides the best understanding of how this emerging treatment works and can guide future research and clinical applications.

Read More »

Identification of Blood Biomarkers of Psilocybin-Assisted Therapy Treatment Response for Generalised Anxiety Disorder

mycolabadmin

Researchers studied how psilocybin-assisted therapy works for people with anxiety disorders by examining blood samples from patients who responded well to treatment versus those who didn’t. They identified four genes whose expression patterns could help predict which anxiety patients would benefit from psilocybin therapy before starting treatment. This breakthrough could help doctors avoid giving intensive treatment to patients unlikely to respond and instead direct them toward more effective alternatives.

Read More »

Norpsilocin: freebase and fumarate salt

mycolabadmin

Researchers determined the crystal structures of norpsilocin, a naturally occurring compound found in magic mushrooms that is chemically similar to psilocin. This work is important because norpsilocin appears to be as potent as psilocin at serotonin receptors and may contribute to the therapeutic effects of magic mushroom extracts. By obtaining pure crystalline forms and understanding the compound’s structure, scientists can better study its properties and potential medical applications for treating conditions like depression and anxiety.

Read More »

Psilocybin During the Postpartum Period Induces Long-Lasting Adverse Effects in Both Mothers and Offspring

mycolabadmin

A new study shows that psilocybin, a psychedelic compound being tested for postpartum depression, may actually cause harm during the breastfeeding period. While the drug helped non-pregnant mice feel less anxious, it made postpartum mothers more anxious and worsened their caregiving behaviors. Even more concerning, baby mice exposed to psilocybin through breast milk developed mood and social problems as adults, suggesting potential lasting risks for human infants.

Read More »

Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey

mycolabadmin

This survey studied how autistic adults feel about using psychedelics like psilocybin mushrooms for mental health. Nearly 70% of participants had tried psychedelics before and most found them helpful for anxiety and depression. Many participants were interested in trying them or participating in research, though legal and practical barriers stood in the way. The study suggests that psychedelics could be a promising treatment option for autistic people with mental health challenges.

Read More »

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

mycolabadmin

This study tested whether psilocybin (an active compound from magic mushrooms) combined with eugenol (a natural compound from cloves) could reduce brain inflammation in mice. Researchers gave mice a substance that triggers inflammation in the brain and then treated them with these compounds before or after the inflammation started. The combination treatment, especially at a 1:50 ratio of psilocybin to eugenol, significantly reduced multiple inflammatory markers in the brain, suggesting this combination could potentially be helpful for treating brain inflammation-related conditions.

Read More »
Scroll to Top